Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add filters

Database
Document Type
Year range
1.
Praxis (Bern 1994) ; 110(3): 141-142, 2021.
Article in German | MEDLINE | ID: covidwho-1114688

ABSTRACT

CME/Answers: Hypertension and the COVID-19 Pandemic: What to Consider in Medical Practice Abstract. The COVID-19 pandemic represents a major public health problem. A fraction of the population is at increased risk of developing complications of this disease, in particular older subjects as well as diabetic, obese and hypertensive patients. With regard to patients with high blood pressure, the existence of an increased risk remains to be confirmed in large controlled trials. So far the findings regarding this question are reassuring, whether these patients are treated or not. There seems to be no reason to worry when using blockers of the renin-angiotensin system. The observations available to date suggest that COVID-19 vaccine can be administered safely to hypertensive patients. In conclusion, there is no reason to implement changes in the care of hypertensive patients due to the pandemic.


Subject(s)
COVID-19 , Hypertension , Angiotensin-Converting Enzyme Inhibitors/pharmacology , Antihypertensive Agents/therapeutic use , COVID-19 Vaccines , Humans , Hypertension/drug therapy , Hypertension/epidemiology , Pandemics , Renin-Angiotensin System , SARS-CoV-2
2.
Praxis (Bern 1994) ; 110(2): 60-64, 2021 Feb.
Article in German | MEDLINE | ID: covidwho-1084605

ABSTRACT

CME: Hypertension and the COVID-19 Pandemic: What to Consider in Medical Practice Abstract. The COVID-19 pandemic represents a major public health problem. A fraction of the population is at increased risk of developing complications of this disease, in particular older subjects as well as diabetic, obese and hypertensive patients. With regard to patients with high blood pressure, the existence of an increased risk remains to be confirmed in large controlled trials. So far the findings regarding this question are reassuring, whether these patients are treated or not. There seems to be no reason to worry when using blockers of the renin-angiotensin system. The observations available to date suggest that COVID-19 vaccine can be administered safely to hypertensive patients. In conclusion, there is no reason to implement changes in the care of hypertensive patients due to the pandemic.


Subject(s)
COVID-19 , Hypertension , Angiotensin-Converting Enzyme Inhibitors/pharmacology , Antihypertensive Agents/pharmacology , Antihypertensive Agents/therapeutic use , COVID-19 Vaccines , Humans , Hypertension/drug therapy , Hypertension/epidemiology , Pandemics , Renin-Angiotensin System , SARS-CoV-2
3.
Praxis (Bern 1994) ; 110(2): 1-5, 2021 Feb.
Article in French | MEDLINE | ID: covidwho-1061211

ABSTRACT

CME: Hypertension and the COVID-19 Pandemic: What to Consider in Medical Practice Abstract. The COVID-19 pandemic represents a major public health problem. A fraction of the population is at increased risk of developing complications of this disease, in particular older subjects as well as diabetic, obese and hypertensive patients. With regard to patients with high blood pressure, the existence of an increased risk remains to be confirmed in large controlled trials. So far the findings regarding this question are reassuring, whether these patients are treated or not. There seems to be no reason to worry when using blockers of the renin-angiotensin system. The observations available to date suggest that COVID-19 vaccine can be administered safely to hypertensive patients. In conclusion, there is no reason to implement changes in the care of hypertensive patients due to the pandemic.


Résumé. La pandémie COVID-19 représente un problème de santé publique majeur. Une partie de la population est à risque accru de développer des complications de cette maladie, en particulier les personnes âgées ainsi que les malades diabétiques, les obèses et, possiblement, les malades hypertendus. Pour ces derniers, cela reste à être confirmé dans des études contrôlées de grande envergure. Les connaissances accumulées à ce jour sont rassurantes, que les malades soient traités ou non. Il n'y a pas de crainte à avoir en ce qui concerne la prise de médicaments antihypertenseurs, y compris les bloqueurs du système rénine-angiotensine. Les premières observations indiquent que le vaccin anti-COVID-19 peut être administré chez le malade hypertendu avec la meme efficacité que le normotendu. En conclusion il n'y a pas de raison de prendre en charge le malade hypertendu autrement qu'avant l'apparition de la pandémie.


Subject(s)
COVID-19 , Hypertension , Angiotensin-Converting Enzyme Inhibitors/pharmacology , Antihypertensive Agents/pharmacology , Antihypertensive Agents/therapeutic use , COVID-19 Vaccines , Humans , Hypertension/drug therapy , Hypertension/epidemiology , Pandemics , Renin-Angiotensin System , SARS-CoV-2
SELECTION OF CITATIONS
SEARCH DETAIL